Advocacy intelligence hub — real-time data for patient organizations
Ucephan: FDA approved
For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Ucephan
ImmunexImmunex
Ucephan
(Benzoate and phenylacetate)Orphan drugImmunexImmunex